FDA Approves Multiple Novel Cancer Therapeutics, Including Multi-Selective RAS(ON) Inhibitor Daraxonrasib and Next-Gen ADCs for Difficult-to-Treat Cancers

September 20, 2026

The ASCO Post USA

Overview

The U.S. FDA announced several groundbreaking cancer drug approvals on September 10, 2026, including daraxonrasib, a multi-selective RAS(ON) inhibitor, for metastatic pancreatic adenocarcinoma. Other approvals include datopotamab deruxtecan-dlnk (ADC) for triple-negative breast cancer and zenocutuzumab-zbco (bispecific antibody) for NRG1-mutated cholangiocarcinoma. These regulatory decisions significantly expand treatment options for patients with difficult-to-treat cancers, underscoring the shift towards precision oncology and advanced targeted therapies.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) announced a series of pivotal approvals on September 10, 2026, introducing novel and expanded indications for several cancer therapeutics that promise to redefine treatment paradigms. A standout among these is the approval of daraxonrasib, a multi-selective RAS(ON) inhibitor, for metastatic pancreatic adenocarcinoma, an aggressive cancer historically resistant to effective therapies. This approval offers new hope and potentially prolonged survival for patients with this challenging diagnosis. Further reinforcing the precision oncology trend, approvals also included advanced antibody-drug conjugates (ADCs) and bispecific antibodies targeting specific genetic mutations and tumor types.

Technical / Clinical Details

Daraxonrasib for Metastatic Pancreatic Adenocarcinoma: Developed by Revolution Medicines, daraxonrasib targets multiple active forms of the RAS protein (RAS(ON)), which are critical drivers in many cancers. The FDA granted Breakthrough Therapy Designation and approval for daraxonrasib in combination with chemotherapy as a first-line treatment for patients with untreated metastatic pancreatic adenocarcinoma. Clinical trials demonstrated a statistically significant improvement in progression-free survival (PFS) and a favorable trend in overall survival (OS) compared to platinum-based chemotherapy regimens, offering a crucial new option for this high-unmet-need population.
Belzutifan + Pembrolizumab for Renal Cell Carcinoma: The combination of belzutifan and pembrolizumab received approval for advanced or metastatic renal cell carcinoma, leveraging the synergistic effects of HIF-2α inhibition and PD-1 blockade to enhance anti-tumor responses.
Capivasertib + Abiraterone for mHSPC: For patients with metastatic hormone-sensitive prostate cancer (mHSPC), the AKT inhibitor capivasertib in combination with the androgen biosynthesis inhibitor abiraterone was approved, potentially delaying progression to castration-resistant disease.
Datopotamab Deruxtecan-dlnk for Triple-Negative Breast Cancer: This antibody-drug conjugate (ADC) was approved for previously treated locally advanced or metastatic triple-negative breast cancer (TNBC). The ADC selectively delivers a cytotoxic payload to tumor cells, demonstrating high response rates and a manageable safety profile in clinical studies.
Zenocutuzumab-zbco for NRG1-Mutated Cholangiocarcinoma: The bispecific antibody zenocutuzumab-zbco received approval for patients with locally advanced or metastatic cholangiocarcinoma harboring NRG1 gene fusions. This agent simultaneously targets HER2 and HER3, disrupting the oncogenic signaling driven by NRG1 fusions.
Sevabertinib for HER2-Mutant Lung Cancer: Sevabertinib, an oral HER2-selective inhibitor, was approved for non-small cell lung cancer (NSCLC) patients with activating HER2 mutations. These approvals collectively underscore the profound impact of molecularly targeted therapies and individualized medicine in improving patient outcomes across a spectrum of difficult-to-treat cancers.

Background & Context

The field of oncology has steadily shifted towards precision medicine, focusing on therapies that target specific genetic mutations or protein expressions driving tumor growth. The approval of daraxonrasib is particularly notable as the RAS pathway, long considered ‘undruggable,’ is a central oncogenic driver in a significant proportion of human cancers. The concurrent approvals of various modalities—ADCs, bispecific antibodies, and selective kinase inhibitors—reflect a deepening understanding of tumor biology and the increasing sophistication of therapeutic design. These treatments are not only potent as monotherapies but also show enhanced efficacy in combination with existing standards of care, promising to reshape future treatment guidelines and clinical practice.

Strategic Significance & Outlook

These FDA approvals are strategically significant, offering expanded treatment portfolios for pharmaceutical companies and enhanced options for oncologists and patients globally. The success of daraxonrasib opens up new avenues for targeting RAS-driven cancers beyond pancreatic cancer, including lung and colorectal cancers. The continuous evolution of ADC technology suggests further optimization of payloads and discovery of novel targets, while bispecific antibodies represent the vanguard of multi-targeted antibody therapies designed for synergistic effects. These developments will likely accelerate R&D investments in novel modalities, foster greater collaboration across the biopharmaceutical ecosystem, and drive the broader adoption of personalized medicine. The ongoing collection of real-world evidence and patient data will be crucial for optimizing the use and further development of these advanced therapeutic agents, cementing their impact on global cancer care.

Source: https://ascopost.com/Departments?D=FDA%20Update

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.